Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 4/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288508 | 0.89 | PRKAA2 (0.44) | PRKAA2CSF1RPDGFRBKITDDR1 | |
| SCHEMBL5143997 | 0.86 | EPHX2 (0.48) | PRKAA2CSF1RPDGFRBKITDDR1 | |
| SCHEMBL5144228 | 0.86 | EPHX2 (0.45) | — | |
| SCHEMBL5298159 | 0.84 | MAPT (0.44) | PRKAA2RXFP1 | |
| SCHEMBL5143816 | 0.84 | PRKAA2 (0.41) | PRKAA2SCN9A | |
| SCHEMBL5145627 | 0.84 | EPHX2 (0.43) | PRKAA2 | |
| SCHEMBL5142098 | 0.84 | KMT2A (0.45) | PRKAA2 | |
| SCHEMBL3289150 | 0.84 | SMO (0.44) | PRKAA2SCD5RXFP2RXFP1PGR | |
| SCHEMBL3317661 | 0.84 | L3MBTL1 (0.44) | PRKAA2CSF1RPDGFRBKITDDR1 | |
| SCHEMBL3290058 | 0.83 | CFD (0.42) | RXFP1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | PRKAA2 2191/4885CSF1R 1152/4885PDGFRB 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.